Alimera Sciences Inc (NASDAQ:ALIM)

Data as of Oct 20
 +0.03 / +0.62%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Alimera Sciences, Inc. is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. It focuses on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies. Alimera Sciences was founded on June 4, 2003 by C. Daniel Myers and David R. Holland and is headquartered in Alpharetta, GA.

Contact Information

Alimera Sciences, Inc.
6120 Windward Parkway
Alpharetta Georgia 30005
P:(678) 990-5740
Investor Relations:



Individual stakeholders55.60%
Mutual fund holders5.01%
Other institutional36.14%

Top Executives

Charles Daniel MyersPresident, Chief Executive Officer & Director
Richard S. EiswirthSecretary, Chief Operating & Financial Officer
Kenneth GreenChief Scientific Officer & Senior Vice President
Susan H. CaballaSenior VP-Regulatory & Technical Affairs
David R. HollandSenior Vice President-Sales & Marketing

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.